Muscle Growth Research Stack — Research Stack Protocol (2026)
⚠️ Research Use Only. This post is educational and does not constitute medical advice. All peptides discussed are sold for research purposes only. See our full disclaimer.
Anabolic stack for hypertrophy research with recovery support
Overview
The muscle growth stack combines growth hormone stimulation, direct IGF-1 receptor activation, and recovery support. It targets both the anabolic signaling and the recovery infrastructure needed to support increased training volume.
Peptides in This Stack
CJC-1295
Growth Hormone · Moderate
CJC-1295 is a long-acting GHRH analogue studied for sustained growth hormone release, often combined with Ipamorelin.
Ipamorelin
Growth Hormone · Moderate
Ipamorelin is a selective growth hormone secretagogue studied for its ability to stimulate GH release with minimal side effects.
IGF-1 LR3
Growth Hormone · Moderate
IGF-1 LR3 is a modified, longer-acting version of insulin-like growth factor-1, studied for cell growth and muscle hypertrophy research.
BPC-157
Healing & Recovery · High
BPC-157 is one of the most researched healing peptides, studied extensively for tendon, ligament, and gut repair in animal models.
Stack Rationale
CJC-1295 and Ipamorelin together produce sustained GH elevation through complementary mechanisms. IGF-1 LR3 directly activates IGF-1 receptors, bypassing the GH-to-IGF-1 conversion step. BPC-157 supports tendon and connective tissue recovery, addressing the bottleneck that often limits hypertrophy programs.
Research Protocol
Sample protocol: CJC-1295 (no DAC) 100 mcg + Ipamorelin 200 mcg subq, 2-3x daily (pre-bed, post-workout, optionally morning). IGF-1 LR3 20-40 mcg subq post-workout 4-5 days/week. BPC-157 250-500 mcg subq daily. Run 8-12 weeks then break.
The above represents protocols reported in research literature and research community use. These are not recommendations for human dosing or self-administration.
Reported Research Outcomes
Research literature suggests improved recovery between training sessions, increased lean mass, and reduced injury rate at high training volumes. Strength gains beyond what training alone would produce are harder to characterize.
Cautions & Considerations
IGF-1 LR3 carries hypoglycemia risk and theoretical cancer concerns from elevated IGF-1 signaling. WADA bans all of these compounds for competitive athletes. Not appropriate for adolescent or young adult researchers with developing endocrine systems.
Research Use Only — Compliance Notice
The peptides discussed in this stack are sold for research purposes only. None of this content is medical advice or intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Always consult a qualified medical professional before considering any peptide-related protocols.
